{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T13:12:46Z","timestamp":1784380366677,"version":"3.55.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T00:00:00Z","timestamp":1637193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T00:00:00Z","timestamp":1637193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI117001"],"award-info":[{"award-number":["AI117001"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["TR001870"],"award-info":[{"award-number":["TR001870"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Intermittent preventive treatment (IPT) with dihydroartemisinin-piperaquine (DP) is highly protective against malaria in children, but is not standard in malaria-endemic countries. Optimal DP dosing regimens will maximize efficacy and reduce toxicity and resistance selection. We analyze piperaquine (PPQ) concentrations (<jats:italic>n<\/jats:italic>\u2009=\u20094573), malaria incidence data (<jats:italic>n<\/jats:italic>\u2009=\u2009326), and <jats:italic>P. falciparum<\/jats:italic> drug resistance markers from a trial of children randomized to IPT with DP every 12 weeks (<jats:italic>n<\/jats:italic>\u2009=\u2009184) or every 4 weeks (<jats:italic>n<\/jats:italic>\u2009=\u200996) from 2 to 24 months of age (NCT02163447). We use nonlinear mixed effects modeling to establish malaria protective PPQ levels and risk factors for suboptimal protection. Compared to DP every 12 weeks, DP every 4 weeks is associated with 95% protective efficacy (95% CI: 84\u201399%). A PPQ level of 15.4\u2009ng\/mL reduces the malaria hazard by 95%. Malnutrition reduces PPQ exposure. In simulations, we show that DP every 4 weeks is optimal across a range of transmission intensities, and age-based dosing improves malaria protection in young or malnourished children.<\/jats:p>","DOI":"10.1038\/s41467-021-27051-8","type":"journal-article","created":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T11:06:20Z","timestamp":1637233580000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Identifying an optimal dihydroartemisinin-piperaquine dosing regimen for malaria prevention in young Ugandan children"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1166-1587","authenticated-orcid":false,"given":"Erika","family":"Wallender","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Mohamed","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abel","family":"Kakuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6305-758X","authenticated-orcid":false,"given":"Prasanna","family":"Jagannathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Kakuru","family":"Muhindo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bishop","family":"Opira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Whalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2702-4486","authenticated-orcid":false,"given":"Liusheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marvin","family":"Duvalsaint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Legac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moses R.","family":"Kamya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant","family":"Dorsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Aweeka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3143-5579","authenticated-orcid":false,"given":"Rada M.","family":"Savic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,18]]},"reference":[{"key":"27051_CR1","unstructured":"World Health Organization. World Malaria Report 2019 (WHO, Geneva, Switzerland, 2019)."},{"key":"27051_CR2","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-020-01675-x","volume":"18","author":"A Kakuru","year":"2020","unstructured":"Kakuru, A. et al. Impact of intermittent preventive treatment of malaria in pregnancy with dihydroartemisinin-piperaquine versus sulfadoxine-pyrimethamine on the incidence of malaria in infancy: a randomized controlled trial. BMC Med. 18, 207 (2020).","journal-title":"BMC Med."},{"key":"27051_CR3","doi-asserted-by":"crossref","first-page":"e1001689","DOI":"10.1371\/journal.pmed.1001689","volume":"11","author":"V Bigira","year":"2014","unstructured":"Bigira, V. et al. Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: a randomized controlled trial. PLoS Med. 11, e1001689 (2014).","journal-title":"PLoS Med."},{"key":"27051_CR4","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1128\/AAC.04923-14","volume":"59","author":"I Zongo","year":"2015","unstructured":"Zongo, I. et al. Randomized noninferiority trial of dihydroartemisinin-piperaquine compared with sulfadoxine-pyrimethamine plus amodiaquine for seasonal malaria chemoprevention in Burkina Faso. Antimicrob. Agents Chemother. 59, 4387\u20134396 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"27051_CR5","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(20)32227-3","volume":"396","author":"Access-Smc Partnership.","year":"2020","unstructured":"Access-Smc Partnership. Effectiveness of seasonal malaria chemoprevention at scale in west and central Africa: an observational study. Lancet 396, 1829\u20131840 (2020).","journal-title":"Lancet"},{"key":"27051_CR6","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1097\/QAD.0000000000000497","volume":"28","author":"MR Kamya","year":"2014","unstructured":"Kamya, M. R. et al. Efficacy and safety of three regimens for the prevention of malaria in young HIV-exposed Ugandan children: a randomized controlled trial. AIDS 28, 2701\u20132709 (2014).","journal-title":"AIDS"},{"key":"27051_CR7","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2165\/00003088-200847020-00002","volume":"47","author":"PI German","year":"2008","unstructured":"German, P. I. & Aweeka, F. T. Clinical pharmacology of artemisinin-based combination therapies. Clin. Pharmacokinet. 47, 91\u2013102 (2008).","journal-title":"Clin. Pharmacokinet."},{"key":"27051_CR8","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S1473-3099(19)30299-3","volume":"19","author":"MK Muhindo","year":"2019","unstructured":"Muhindo, M. K. et al. Intermittent preventive treatment with dihydroartemisinin-piperaquine and risk of malaria following cessation in young Ugandan children: a double-blind, randomised, controlled trial. Lancet Infect. Dis. 19, 962\u2013972 (2019).","journal-title":"Lancet Infect. Dis."},{"key":"27051_CR9","doi-asserted-by":"crossref","first-page":"e668","DOI":"10.1016\/S2214-109X(18)30126-8","volume":"6","author":"SG Staedke","year":"2018","unstructured":"Staedke, S. G. et al. Assessment of community-level effects of intermittent preventive treatment for malaria in schoolchildren in Jinja, Uganda (START-IPT trial): a cluster-randomised trial. Lancet Glob. Health 6, e668\u2013e679 (2018).","journal-title":"Lancet Glob. Health"},{"key":"27051_CR10","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S1473-3099(18)30297-4","volume":"18","author":"XHS Chan","year":"2018","unstructured":"Chan, X. H. S. et al. Risk of sudden unexplained death after use of dihydroartemisinin-piperaquine for malaria: a systematic review and Bayesian meta-analysis. Lancet Infect. Dis. 18, 913\u2013923 (2018).","journal-title":"Lancet Infect. Dis."},{"key":"27051_CR11","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1111\/bcp.13372","volume":"83","author":"P Chotsiri","year":"2017","unstructured":"Chotsiri, P. et al. Population pharmacokinetics and electrocardiographic effects of dihydroartemisinin-piperaquine in healthy volunteers. Br. J. Clin. Pharm. 83, 2752\u20132766 (2017).","journal-title":"Br. J. Clin. Pharm."},{"key":"27051_CR12","doi-asserted-by":"crossref","first-page":"260ra147","DOI":"10.1126\/scitranslmed.3005311","volume":"6","author":"M Bergstrand","year":"2014","unstructured":"Bergstrand, M. et al. Characterization of an in vivo concentration-effect relationship for piperaquine in malaria chemoprevention. Sci. Transl. Med. 6, 260ra147 (2014).","journal-title":"Sci. Transl. Med."},{"key":"27051_CR13","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-08297-9","volume":"10","author":"P Chotsiri","year":"2019","unstructured":"Chotsiri, P. et al. Optimal dosing of dihydroartemisinin-piperaquine for seasonal malaria chemoprevention in young children. Nat. Commun. 10, 480 (2019).","journal-title":"Nat. Commun."},{"key":"27051_CR14","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1128\/AAC.00012-07","volume":"51","author":"SL Nsobya","year":"2007","unstructured":"Nsobya, S. L., Dokomajilar, C., Joloba, M., Dorsey, G. & Rosenthal, P. J. Resistance-mediating Plasmodium falciparum pfcrt and pfmdr1 alleles after treatment with artesunate-amodiaquine in Uganda. Antimicrob. Agents Chemother. 51, 3023\u20133025 (2007).","journal-title":"Antimicrob. Agents Chemother."},{"key":"27051_CR15","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1093\/cid\/ciy218","volume":"67","author":"RM Savic","year":"2018","unstructured":"Savic, R. M. et al. Intermittent preventive treatment for malaria in pregnancy: optimization of target concentrations of of dihydroartemisinin-piperaquine. Clin. Infect. Dis. 67, 1079\u20131088 (2018).","journal-title":"Clin. Infect. Dis."},{"key":"27051_CR16","doi-asserted-by":"crossref","first-page":"e1003214","DOI":"10.1371\/journal.pmed.1003214","volume":"17","author":"ME Cairns","year":"2020","unstructured":"Cairns, M. E. et al. Evaluation of seasonal malaria chemoprevention in two areas of intense seasonal malaria transmission: secondary analysis of a household-randomised, placebo-controlled trial in Hounde District, Burkina Faso and Bougouni District, Mali. PLoS Med. 17, e1003214 (2020).","journal-title":"PLoS Med."},{"key":"27051_CR17","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/cpt.1531","volume":"106","author":"P Chotsiri","year":"2019","unstructured":"Chotsiri, P. et al. Severe acute malnutrition results in lower lumefantrine exposure in children treated with artemether-lumefantrine for uncomplicated malaria. Clin. Pharm. Ther. 106, 1299\u20131309 (2019).","journal-title":"Clin. Pharm. Ther."},{"key":"27051_CR18","doi-asserted-by":"crossref","first-page":"e01370","DOI":"10.1128\/AAC.01370-17","volume":"62","author":"M de Kock","year":"2018","unstructured":"de Kock, M. et al. Population pharmacokinetic properties of sulfadoxine and pyrimethamine: a pooled analysis to inform optimal dosing in African children with uncomplicated malaria. Antimicrob. Agents Chemother. 62, e01370\u201317 (2018).","journal-title":"Antimicrob. Agents Chemother."},{"key":"27051_CR19","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-016-0716-1","volume":"14","author":"L Denoeud-Ndam","year":"2016","unstructured":"Denoeud-Ndam, L. et al. Efficacy of artemether-lumefantrine in relation to drug exposure in children with and without severe acute malnutrition: an open comparative intervention study in Mali and Niger. BMC Med. 14, 167 (2016).","journal-title":"BMC Med."},{"key":"27051_CR20","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-015-0456-7","volume":"13","author":"WorldWide Antimalarial Resistance Network (WWARN) Lumefantrine PK\/PD Study Group.","year":"2015","unstructured":"WorldWide Antimalarial Resistance Network (WWARN) Lumefantrine PK\/PD Study Group. Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data. BMC Med. 13, 227 (2015).","journal-title":"BMC Med."},{"key":"27051_CR21","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1743-7075-6-50","volume":"6","author":"KA Oshikoya","year":"2009","unstructured":"Oshikoya, K. A. & Senbanjo, I. O. Pathophysiological changes that affect drug disposition in protein-energy malnourished children. Nutr. Metab. 6, 50 (2009).","journal-title":"Nutr. Metab."},{"key":"27051_CR22","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S2352-4642(19)30196-8","volume":"3","author":"KK Radtke","year":"2019","unstructured":"Radtke, K. K. et al. Alternative dosing guidelines to improve outcomes in childhood tuberculosis: a mathematical modelling study. Lancet Child Adolesc. Health 3, 636\u2013645 (2019).","journal-title":"Lancet Child Adolesc. Health"},{"key":"27051_CR23","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1002\/cpt.1707","volume":"107","author":"J Ding","year":"2020","unstructured":"Ding, J. et al. Adherence and population pharmacokinetic properties of amodiaquine when used for seasonal malaria chemoprevention in African Children. Clin. Pharm. Ther. 107, 1179\u20131188 (2020).","journal-title":"Clin. Pharm. Ther."},{"key":"27051_CR24","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/cid\/cir498","volume":"53","author":"KE Mace","year":"2011","unstructured":"Mace, K. E. et al. Adherence to treatment with artemether-lumefantrine for uncomplicated malaria in rural Malawi. Clin. Infect. Dis. 53, 772\u2013779 (2011).","journal-title":"Clin. Infect. Dis."},{"key":"27051_CR25","doi-asserted-by":"crossref","DOI":"10.1186\/s12936-015-0933-7","volume":"14","author":"S Gerstl","year":"2015","unstructured":"Gerstl, S. et al. High adherence to malaria treatment: promising results of an adherence study in South Kivu, Democratic Republic of the Congo. Malar. J. 14, 414 (2015).","journal-title":"Malar. J."},{"key":"27051_CR26","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1128\/AAC.02318-13","volume":"58","author":"J Tarning","year":"2014","unstructured":"Tarning, J. et al. Population pharmacokinetic assessment of the effect of food on piperaquine bioavailability in patients with uncomplicated malaria. Antimicrob. Agents Chemother. 58, 2052\u20132058 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"27051_CR27","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s40261-015-0312-8","volume":"35","author":"SE Reuter","year":"2015","unstructured":"Reuter, S. E. et al. Effect of food on the pharmacokinetics of piperaquine and dihydroartemisinin. Clin. Drug Investig. 35, 559\u2013567 (2015).","journal-title":"Clin. Drug Investig."},{"key":"27051_CR28","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/infdis\/jiw301","volume":"214","author":"I Rodriguez-Barraquer","year":"2016","unstructured":"Rodriguez-Barraquer, I. et al. Quantifying heterogeneous malaria exposure and clinical protection in a cohort of Ugandan children. J. Infect. Dis. 214, 1072\u20131080 (2016).","journal-title":"J. Infect. Dis."},{"key":"27051_CR29","doi-asserted-by":"crossref","DOI":"10.1186\/1475-2875-11-400","volume":"11","author":"U D\u2019Alessandro","year":"2012","unstructured":"D\u2019Alessandro, U. et al. Malaria in infants aged less than six months - is it an area of unmet medical need? Malar. J. 11, 400 (2012).","journal-title":"Malar. J."},{"key":"27051_CR30","doi-asserted-by":"crossref","first-page":"e01393","DOI":"10.1128\/AAC.01393-18","volume":"63","author":"E Wallender","year":"2019","unstructured":"Wallender, E. et al. Modeling prevention of malaria and selection of drug resistance with different dosing schedules of dihydroartemisinin-piperaquine preventive therapy during pregnancy in Uganda. Antimicrob. Agents Chemother. 63, e01393\u201318 (2019).","journal-title":"Antimicrob. Agents Chemother."},{"key":"27051_CR31","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1128\/AAC.00903-07","volume":"52","author":"K Stepniewska","year":"2008","unstructured":"Stepniewska, K. & White, N. J. Pharmacokinetic determinants of the window of selection for antimalarial drug resistance. Antimicrob. Agents Chemother. 52, 1589\u20131596 (2008).","journal-title":"Antimicrob. Agents Chemother."},{"key":"27051_CR32","doi-asserted-by":"crossref","unstructured":"Asua, V. et al. Changing prevalence of potential mediators of aminoquinoline, antifolate, and artemisinin resistance across Uganda. J. Infect. Dis. 223, 985\u2013994 (2020).","DOI":"10.1093\/infdis\/jiaa687"},{"key":"27051_CR33","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/s41591-020-1005-2","volume":"26","author":"A Uwimana","year":"2020","unstructured":"Uwimana, A. et al. Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda. Nat. Med. 26, 1602\u20131608 (2020).","journal-title":"Nat. Med."},{"key":"27051_CR34","doi-asserted-by":"crossref","unstructured":"Uwimana, A. et al. Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study. Lancet Infect. Dis. 21, 1120\u20131128 (2021).","DOI":"10.1016\/S1473-3099(21)00142-0"},{"key":"27051_CR35","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1093\/infdis\/jiaa687","volume":"223","author":"V Asua","year":"2021","unstructured":"Asua, V. et al. Changing prevalence of potential mediators of aminoquinoline, antifolate, and artemisinin resistance across Uganda. J. Infect. Dis. 223, 985\u2013994 (2021).","journal-title":"J. Infect. Dis."},{"key":"27051_CR36","doi-asserted-by":"crossref","unstructured":"Asua, V. et al. Changing molecular markers of antimalarial drug sensitivity across Uganda. Antimicrob. Agents Chemother. 63, e01818-18 (2019).","DOI":"10.1128\/AAC.01818-18"},{"key":"27051_CR37","doi-asserted-by":"crossref","first-page":"e338","DOI":"10.1016\/S1473-3099(19)30261-0","volume":"19","author":"MD Conrad","year":"2019","unstructured":"Conrad, M. D. & Rosenthal, P. J. Antimalarial drug resistance in Africa: the calm before the storm? Lancet Infect. Dis. 19, e338\u2013e351 (2019).","journal-title":"Lancet Infect. Dis."},{"key":"27051_CR38","doi-asserted-by":"crossref","first-page":"e01848","DOI":"10.1128\/AAC.01848-19","volume":"64","author":"T Wattanakul","year":"2020","unstructured":"Wattanakul, T. et al. Pooled multicenter analysis of cardiovascular safety and population pharmacokinetic properties of piperaquine in african patients with uncomplicated Falciparum malaria. Antimicrob. Agents Chemother. 64, e01848\u201319 (2020).","journal-title":"Antimicrob. Agents Chemother."},{"key":"27051_CR39","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1093\/cid\/ciy218","volume":"67","author":"RM Savic","year":"2018","unstructured":"Savic, R. M. et al. Intermittent preventive treatment for malaria in pregnancy: optimization of target concentrations of dihydroartemisinin-piperaquine. Clin. Infect. Dis. 67, 1079\u20131088 (2018).","journal-title":"Clin. Infect. Dis."},{"key":"27051_CR40","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1093\/infdis\/jix660","volume":"217","author":"E Wallender","year":"2018","unstructured":"Wallender, E. et al. Predicting optimal dihydroartemisinin-piperaquine regimens to prevent malaria during pregnancy for human immunodeficiency virus-infected women receiving efavirenz. J. Infect. Dis. 217, 964\u2013972 (2018).","journal-title":"J. Infect. Dis."},{"key":"27051_CR41","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1093\/heapol\/czx084","volume":"32","author":"C Pitt","year":"2017","unstructured":"Pitt, C. et al. Large-scale delivery of seasonal malaria chemoprevention to children under 10 in Senegal: an economic analysis. Health Policy Plan 32, 1256\u20131266 (2017).","journal-title":"Health Policy Plan"},{"key":"27051_CR42","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms1879","volume":"3","author":"M Cairns","year":"2012","unstructured":"Cairns, M. et al. Estimating the potential public health impact of seasonal malaria chemoprevention in African children. Nat. Commun. 3, 881 (2012).","journal-title":"Nat. Commun."},{"key":"27051_CR43","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1056\/NEJMoa1509150","volume":"374","author":"A Kakuru","year":"2016","unstructured":"Kakuru, A. et al. Dihydroartemisinin-piperaquine for the prevention of malaria in pregnancy. N. Engl. J. Med 374, 928\u2013939 (2016).","journal-title":"N. Engl. J. Med"},{"key":"27051_CR44","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1002\/cpt.1534","volume":"106","author":"ME Whalen","year":"2019","unstructured":"Whalen, M. E. et al. Reduced exposure to piperaquine, compared to adults, in young children receiving dihydroartemisinin-piperaquine as malaria chemoprevention. Clin. Pharm. Ther. 106, 1310\u20131318 (2019).","journal-title":"Clin. Pharm. Ther."},{"key":"27051_CR45","doi-asserted-by":"crossref","first-page":"e0233893","DOI":"10.1371\/journal.pone.0233893","volume":"15","author":"N Mwebaza","year":"2020","unstructured":"Mwebaza, N. et al. Determination of piperaquine concentration in human plasma and the correlation of capillary versus venous plasma concentrations. PLoS ONE 15, e0233893 (2020).","journal-title":"PLoS ONE"},{"key":"27051_CR46","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1128\/JCM.00904-13","volume":"51","author":"NP LeClair","year":"2013","unstructured":"LeClair, N. P. et al. Optimization of a ligase detection reaction-fluorescent microsphere assay for characterization of resistance-mediating polymorphisms in African samples of Plasmodium falciparum. J. Clin. Microbiol. 51, 2564\u20132570 (2013).","journal-title":"J. Clin. Microbiol."},{"key":"27051_CR47","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1023\/A:1012299115260","volume":"28","author":"SL Beal","year":"2001","unstructured":"Beal, S. L. Ways to fit a PK model with some data below the quantification limit. J. Pharmacokinet. Pharmacodyn. 28, 481\u2013504 (2001).","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"27051_CR48","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/psp4.12161","volume":"6","author":"TH Nguyen","year":"2017","unstructured":"Nguyen, T. H. et al. Model evaluation of continuous data pharmacometric models: metrics and graphics. CPT Pharmacomet. Syst. Pharm. 6, 87\u2013109 (2017).","journal-title":"CPT Pharmacomet. Syst. Pharm."},{"key":"27051_CR49","doi-asserted-by":"crossref","first-page":"e1002212","DOI":"10.1371\/journal.pmed.1002212","volume":"14","author":"RM Hoglund","year":"2017","unstructured":"Hoglund, R. M. et al. Population pharmacokinetic properties of piperaquine in Falciparum malaria: an individual participant data meta-analysis. PLoS Med. 14, e1002212 (2017).","journal-title":"PLoS Med."},{"key":"27051_CR50","unstructured":"World Health Organization. (2012). WHO Policy Recommendation: Seasonal Malaria Chemoprevention (SMC) for Plasmodium Falciparum Malaria Control in High Seasonal Transmission Areas of the Sahel Sub-Region in Africa (WHO, Geneva, Switzerland, 2012)."},{"key":"27051_CR51","doi-asserted-by":"crossref","unstructured":"Hughes, E. et al. Piperaquine exposure is altered by pregnancy, hiv, and nutritional status in Ugandan women. Antimicrob. Agents Chemother. 64, e01013-20 (2020).","DOI":"10.1128\/AAC.01013-20"},{"key":"27051_CR52","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1093\/infdis\/jix421","volume":"16","author":"MD Conrad","year":"2017","unstructured":"Conrad, M. D. et al. Impact of intermittent preventive treatment during pregnancy on Plasmodium falciparum drug resistance-mediating polymorphisms in Uganda. J. Infect. Dis. 16, 1008\u20131017 (2017).","journal-title":"J. Infect. Dis."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-27051-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-27051-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-27051-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T18:25:51Z","timestamp":1670005551000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-27051-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,18]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["27051"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-27051-8","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,18]]},"assertion":[{"value":"24 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6714"}}